Which has stronger earnings and valuation, TMDX or SNN?

Smith & Nephew SNATS has higher revenue and earnings than TransMedics Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $668.47M 4.49 $190.29M $3.89 22.30 Smith & Nephew SNATS $6.30B 1.87 $625M N/A N/A

Does the media refer more to TMDX or SNN?

In the previous week, TransMedics Group had 7 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 16 mentions for TransMedics Group and 9 mentions for Smith & Nephew SNATS. TransMedics Group's average media sentiment score of 0.52 beat Smith & Nephew SNATS's score of 0.39 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GMED or TMDX?

In the previous week, TransMedics Group had 11 more articles in the media than Globus Medical. MarketBeat recorded 16 mentions for TransMedics Group and 5 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.87 beat TransMedics Group's score of 0.52 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, GKOS or TMDX?

TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 19.76 -$187.69M -$3.25 N/A TransMedics Group $668.47M 4.49 $190.29M $3.89 22.30

Does the media favor GKOS or TMDX?

In the previous week, TransMedics Group had 11 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for TransMedics Group and 5 mentions for Glaukos. Glaukos' average media sentiment score of 1.00 beat TransMedics Group's score of 0.52 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, PODD or TMDX?

Insulet has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $3.05B 3.10 $247.10M $5.35 25.54 TransMedics Group $668.47M 4.49 $190.29M $3.89 22.30

Does the media prefer PODD or TMDX?

In the previous week, TransMedics Group had 2 more articles in the media than Insulet. MarketBeat recorded 16 mentions for TransMedics Group and 14 mentions for Insulet. Insulet's average media sentiment score of 1.06 beat TransMedics Group's score of 0.52 indicating that Insulet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MMED or TMDX?

In the previous week, TransMedics Group had 11 more articles in the media than MiniMed Group. MarketBeat recorded 16 mentions for TransMedics Group and 5 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.10 beat TransMedics Group's score of 0.52 indicating that MiniMed Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

TransMedics Group (TMDX) Competitors

$86.38 +0.52 (+0.61%)

As of 10:02 AM Eastern

Compare

TMDX vs. SNN, GMED, GKOS, PODD, and MMED

Should you buy TransMedics Group stock or one of its competitors? TransMedics Group's main competitors and comparable companies include Smith & Nephew SNATS (SNN), Globus Medical (GMED), Glaukos (GKOS), Insulet (PODD), and MiniMed Group (MMED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does TransMedics Group compare to Smith & Nephew SNATS?

TransMedics Group (NASDAQ:TMDX) and Smith & Nephew SNATS (NYSE:SNN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Smith & Nephew SNATS has higher revenue and earnings than TransMedics Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$668.47M	4.49	$190.29M	$3.89	22.30
Smith & Nephew SNATS	$6.30B	1.87	$625M	N/A	N/A

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TransMedics Group has a net margin of 22.69% compared to Smith & Nephew SNATS's net margin of 0.00%. TransMedics Group's return on equity of 15.88% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
Smith & Nephew SNATS	N/A	N/A	N/A

TransMedics Group has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

In the previous week, TransMedics Group had 7 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 16 mentions for TransMedics Group and 9 mentions for Smith & Nephew SNATS. TransMedics Group's average media sentiment score of 0.52 beat Smith & Nephew SNATS's score of 0.39 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group presently has a consensus target price of $124.18, indicating a potential upside of 43.14%. Smith & Nephew SNATS has a consensus target price of $31.91, indicating a potential upside of 13.78%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts plainly believe TransMedics Group is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

TransMedics Group beats Smith & Nephew SNATS on 12 of the 14 factors compared between the two stocks.

How does TransMedics Group compare to Globus Medical?

Globus Medical (NYSE:GMED) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

TransMedics Group has a net margin of 22.69% compared to Globus Medical's net margin of 17.02%. TransMedics Group's return on equity of 15.88% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
TransMedics Group	22.69%	15.88%	5.95%

Globus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Globus Medical presently has a consensus target price of $101.77, suggesting a potential upside of 36.47%. TransMedics Group has a consensus target price of $124.18, suggesting a potential upside of 43.14%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

Globus Medical has higher revenue and earnings than TransMedics Group. Globus Medical is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.41	$537.87M	$3.91	19.07
TransMedics Group	$668.47M	4.49	$190.29M	$3.89	22.30

In the previous week, TransMedics Group had 11 more articles in the media than Globus Medical. MarketBeat recorded 16 mentions for TransMedics Group and 5 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.87 beat TransMedics Group's score of 0.52 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Globus Medical beats TransMedics Group on 9 of the 17 factors compared between the two stocks.

How does TransMedics Group compare to Glaukos?

Glaukos (NYSE:GKOS) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Glaukos presently has a consensus price target of $178.08, indicating a potential upside of 4.76%. TransMedics Group has a consensus price target of $124.18, indicating a potential upside of 43.14%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	19.76	-$187.69M	-$3.25	N/A
TransMedics Group	$668.47M	4.49	$190.29M	$3.89	22.30

Glaukos has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market.

99.0% of Glaukos shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 6.9% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, TransMedics Group had 11 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for TransMedics Group and 5 mentions for Glaukos. Glaukos' average media sentiment score of 1.00 beat TransMedics Group's score of 0.52 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has a net margin of 22.69% compared to Glaukos' net margin of -30.68%. TransMedics Group's return on equity of 15.88% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
TransMedics Group	22.69%	15.88%	5.95%

Summary

TransMedics Group beats Glaukos on 12 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to Insulet?

Insulet (NASDAQ:PODD) and TransMedics Group (NASDAQ:TMDX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Insulet has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

Insulet has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$3.05B	3.10	$247.10M	$5.35	25.54
TransMedics Group	$668.47M	4.49	$190.29M	$3.89	22.30

99.7% of TransMedics Group shares are owned by institutional investors. 0.4% of Insulet shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, TransMedics Group had 2 more articles in the media than Insulet. MarketBeat recorded 16 mentions for TransMedics Group and 14 mentions for Insulet. Insulet's average media sentiment score of 1.06 beat TransMedics Group's score of 0.52 indicating that Insulet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has a net margin of 22.69% compared to Insulet's net margin of 12.29%. Insulet's return on equity of 29.29% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
TransMedics Group	22.69%	15.88%	5.95%

Insulet presently has a consensus price target of $195.40, suggesting a potential upside of 43.02%. TransMedics Group has a consensus price target of $124.18, suggesting a potential upside of 43.14%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than Insulet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Insulet beats TransMedics Group on 9 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and TransMedics Group (NASDAQ:TMDX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

TransMedics Group has lower revenue, but higher earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.22B	1.90	-$333M	-$0.68	N/A
TransMedics Group	$668.47M	4.49	$190.29M	$3.89	22.30

In the previous week, TransMedics Group had 11 more articles in the media than MiniMed Group. MarketBeat recorded 16 mentions for TransMedics Group and 5 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.10 beat TransMedics Group's score of 0.52 indicating that MiniMed Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has a net margin of 22.69% compared to MiniMed Group's net margin of 0.00%. TransMedics Group's return on equity of 15.88% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
TransMedics Group	22.69%	15.88%	5.95%

MiniMed Group currently has a consensus target price of $23.77, indicating a potential upside of 9.31%. TransMedics Group has a consensus target price of $124.18, indicating a potential upside of 43.14%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

99.7% of TransMedics Group shares are owned by institutional investors. 0.0% of MiniMed Group shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

TransMedics Group beats MiniMed Group on 11 of the 15 factors compared between the two stocks.

Get TransMedics Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TMDX vs. The Competition

Export

Metric	TransMedics Group	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.00B	$5.43B	$7.16B	$14.28B
Dividend Yield	N/A	1.80%	2.57%	11.70%
P/E Ratio	22.30	25.11	273.26	25.37
Price / Sales	4.49	83.64	672.06	100.08
Price / Cash	20.93	33.03	28.42	34.96
Price / Book	6.29	6.03	10.49	6.24
Net Income	$190.29M	$150.14M	$3.49B	$358.08M
7 Day Performance	-1.72%	-1.37%	-1.14%	-0.70%
1 Month Performance	-2.06%	-3.25%	0.58%	-2.76%
1 Year Performance	-24.09%	9.58%	20.20%	6.72%

TransMedics Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TMDX TransMedics Group	4.3529 of 5 stars	$86.75 +1.0%	$124.18 +43.1%	-25.1%	$3.00B	$668.47M	22.30	898	Insider Trade
SNN Smith & Nephew SNATS	2.5129 of 5 stars	$28.40 +3.3%	$31.91 +12.4%	-24.8%	$11.93B	$6.16B	N/A	16,988	Analyst Upgrade Gap Up
GMED Globus Medical	4.3846 of 5 stars	$75.32 +1.5%	$101.77 +35.1%	+28.9%	$10.11B	$3.14B	19.26	6,000
GKOS Glaukos	1.8631 of 5 stars	$170.01 +1.7%	$178.08 +4.7%	+106.6%	$10.03B	$507.44M	N/A	1,094	Positive News
PODD Insulet	4.4766 of 5 stars	$137.38 +4.1%	$195.40 +42.2%	-59.7%	$9.52B	$2.71B	25.66	5,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TMDX) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransMedics Group (TMDX) Competitors

TMDX vs. SNN, GMED, GKOS, PODD, and MMED

How does TransMedics Group compare to Smith & Nephew SNATS?

Summary

How does TransMedics Group compare to Globus Medical?

Summary

How does TransMedics Group compare to Glaukos?

Summary

How does TransMedics Group compare to Insulet?

Summary

How does TransMedics Group compare to MiniMed Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDX vs. The Competition

TransMedics Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TransMedics Group (TMDX) Competitors

TMDX vs. SNN, GMED, GKOS, PODD, and MMED

How does TransMedics Group compare to Smith & Nephew SNATS?

Which has stronger earnings and valuation, TMDX or SNN?

Do insiders and institutionals believe in TMDX or SNN?

Is TMDX or SNN more profitable?

Which has more risk and volatility, TMDX or SNN?

Does the media refer more to TMDX or SNN?

Do analysts prefer TMDX or SNN?

Summary

How does TransMedics Group compare to Globus Medical?

Is GMED or TMDX more profitable?

Which has more volatility & risk, GMED or TMDX?

Do insiders & institutionals hold more shares of GMED or TMDX?

Do analysts recommend GMED or TMDX?

Which has stronger valuation and earnings, GMED or TMDX?

Does the media prefer GMED or TMDX?

Summary

How does TransMedics Group compare to Glaukos?

Do analysts recommend GKOS or TMDX?

Which has higher earnings and valuation, GKOS or TMDX?

Which has more volatility and risk, GKOS or TMDX?

Do insiders and institutionals have more ownership in GKOS or TMDX?

Does the media favor GKOS or TMDX?

Is GKOS or TMDX more profitable?

Summary

How does TransMedics Group compare to Insulet?

Which has more volatility and risk, PODD or TMDX?

Which has preferable earnings & valuation, PODD or TMDX?

Do insiders & institutionals hold more shares of PODD or TMDX?

Does the media prefer PODD or TMDX?

Is PODD or TMDX more profitable?

Do analysts rate PODD or TMDX?

Summary

How does TransMedics Group compare to MiniMed Group?

Which has better earnings and valuation, MMED or TMDX?

Does the media favor MMED or TMDX?

Is MMED or TMDX more profitable?

Do analysts prefer MMED or TMDX?

Do insiders & institutionals believe in MMED or TMDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDX vs. The Competition

TransMedics Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools